Table 1 Tumor and treatment characteristics by age
All (n = 419) | Age ≤ 40 years (n = 43) | Age41–50 years (n = 98) | Age51–60 years (n = 124) | Age ≥ 61 years (n = 154) | P value | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
cT stage | 0.13 | ||||||||||
0, Tis, 1 | 194 | 46% | 13 | 30% | 44 | 45% | 62 | 50% | 75 | 49% | |
2–4 | 225 | 54% | 30 | 70% | 54 | 55% | 62 | 50% | 79 | 51% | |
pT stage | 0.33 | ||||||||||
0, Tis, 1 | 275 | 66% | 23 | 53% | 68 | 69% | 83 | 67% | 101 | 66% | |
2–4 | 144 | 34% | 20 | 47% | 30 | 31% | 41 | 33% | 53 | 34% | |
Histology | 0.14 | ||||||||||
IDC | 381 | 91% | 36 | 84% | 91 | 93% | 115 | 93% | 139 | 90% | |
ILC | 8 | 2% | 0 | 0% | 3 | 3% | 1 | 1% | 4 | 3% | |
Other | 28 | 7% | 7 | 16% | 3 | 3% | 7 | 6% | 11 | 7% | |
Unknown | 2 | 0% | 0 | 0% | 1 | 1% | 1 | 1% | 0 | 0% | |
Histological grade | N/A | ||||||||||
1 | 68 | 16% | 5 | 12% | 11 | 11% | 19 | 15% | 33 | 21% | |
2 | 123 | 29% | 11 | 26% | 22 | 22% | 36 | 29% | 54 | 35% | |
3 | 72 | 17% | 9 | 21% | 13 | 13% | 20 | 16% | 30 | 20% | |
Unknown | 156 | 37% | 18 | 42% | 52 | 53% | 49 | 40% | 37 | 24% | |
Number of positive nodes | N/A | ||||||||||
0 | 288 | 69% | 33 | 77% | 58 | 59% | 90 | 73% | 107 | 70% | |
1–3 | 105 | 25% | 8 | 18% | 35 | 36% | 25 | 20% | 37 | 24% | |
≥ 4 | 26 | 6% | 2 | 5% | 5 | 5% | 9 | 7% | 10 | 7% | |
Hormonal receptor status | N/A | ||||||||||
Negative | 110 | 26% | 23 | 53% | 26 | 27% | 33 | 27% | 28 | 18% | |
Positive | 296 | 71% | 20 | 47% | 69 | 70% | 86 | 69% | 121 | 79% | |
Unknown | 13 | 3% | 0 | 0% | 3 | 3% | 5 | 4% | 5 | 3% | |
Chemotherapy | 0.002 | ||||||||||
No | 236 | 56% | 19 | 44% | 43 | 44% | 73 | 59% | 101 | 66% | |
Yes | 183 | 44% | 24 | 56% | 55 | 56% | 51 | 41% | 53 | 34% | |
Endocrine therapy | 0.31 | ||||||||||
No | 115 | 27% | 17 | 40% | 27 | 28% | 32 | 26% | 39 | 25% | |
Yes | 304 | 73% | 26 | 60% | 71 | 72% | 92 | 74% | 115 | 75% | |